Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer-Reference-Cited by-同舟云学术

Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer

Published:2021-09-03 Issue:10 Volume:125 Page:1356-1364
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Chatzipli Aikaterini,Bonnefoi Hervé^ORCID,MacGrogan Gaetan,Sentis Julie,Cameron David,Poncet Coralie,Abadie-Lacourtoisie Sophie,Bodmer Alexandre,Brain Etienne,Cufer Tanja,Campone Mario,Luporsi Elisabeth,Moldovan Cristian,Petit Thierry,Piccart Martine,Priou Franck,Senkus Elsbieta,Zaman Khalil,Iggo Richard^ORCID,

Funder

European Organisation for Research and Treatment of Cancer (EORTC) EBCC12

SIRIC-INCa-INSERM-DGOS 6046 Fondation pour la lutte contre le cancer et pour des recherches biologiques

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-021-01526-3.pdf

Reference29 articles.

1. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.

2. Bonnefoi H, Litiere S, Piccart M, MacGrogan G, Fumoleau P, Brain E, et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann Oncol. 2014;25:1128–36.